|
KMID : 0338420100250040372
|
|
The Korean Journal of Internal Medicine
2010 Volume.25 No. 4 p.372 ~ p.376
|
|
|
Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B
|
|
Yang Hyeon-Woong
Lee Byung-Seok
Lee Tae-Hee
Lee Heon-Young
Nam Kwan-Woo
Kang Young-Woo
Chae Hee-Bok
Kim Seok-Hyun
Kim Seok-Bae
Lee Hyang-Le
Kim An-Na
Song Il-Han
Lee Sae-Hwan
Kim Hong-Su
|
|
|
Abstract
|
|
|
Background/Aims: Clevudine, a pyrimidine nucleoside analogue, has potent antiviral effects in patients with chronic viral hepatitis B (CHB). We report the efficacy of initial treatment with clevudine in naive patients with CHB living in Daejeon and Chungcheong Province, South Korea.
Methods: One hundred five adults with CHB were administered 30 mg of clevudine per day for an average of 51 weeks. We evaluated viral markers and liver biochemistry retrospectively every 3 months.
Results: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatitis B virus (HBV) DNA before the treatment were 184 ± 188 IU/L, 150 ± 138 IU/L, and 7.1 ± 1.2 log copies/mL, respectively. Undetectable rates (< 60 IU/mL) of DNA were 36.2%, 68.9%, 83.6%, 76.2%, and 75.8% at 12, 24, 36, 48, and 60 weeks, respectively. Seroconversion rates were 9.1%, 13.6%, 24.6%, 26.5%, and 26.1% and ALT normalization rates were 64.5%, 78.1%, 87.9%, 90.0% at 12, 24, 36, and 48 weeks, respectively. Six patients (5.7%) had a viral breakthrough.
Conclusions: Clevudine is a useful drug in the initial treatment of patients with CHB, with a potent antiviral effect and low incidence of viral breakthrough.
|
|
|
KEYWORD
|
|
|
Clevudine, Drug resistance, HBV seroconversion, Hepatitis B, chronic
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|